The efficiency of chemo-radiotherapy for localized recurrence of esophageal cancer after radical esophagectomy
Keywords:
esophageal cancer, chemoradiation, localized recurrenceAbstract
Background: Radiation therapy for postoperative loco regional recurrence of esophageal cancer has been reported to be effective. The purpose of the present study was to evaluate the usefulness of radiotherapy combined with standard dose 5-fluorouracil (5FU) and cisplatin for the treatment of postoperative loco regional recurrent esophageal cancer. Method: Between 2004 and 2010, 10 patients with postoperative recurrence of esophageal cancer received concurrent chemoradiotherapy (CRT) using 5-FU and cisplatin. We evaluated the response rate, overall survival, and any adverse events. Results: Nine out of 10 patients had mediastinal lymph node recurrence, and 1 patient had a cervical lymph node recurrence. Nine patients were irradiated with 58-64Gy, and 1 patient could not complete CRT due to mediastinitis at 34Gy. Complete response (CR) was recognized in 4 patients (40%), and partial response (PR) in 4 patients (40%). The overall median survival time was 13 months. The histological type was a well-differentiated squamous cell carcinoma in 3 of the 4 patients where CR was obtained. CRT was discontinued with 1 patient who experienced a tracheomediastinal fistula. Because of hemorrhage due to radiation gastritis, transfusion of red cell concentrates was required. Steroids were required to treat intermittent pneumonitis. Conclusion: Chemoradiotherapy using 5-FU and cisplatin for loco regional postoperative recurrence of esophageal cancer was an effective therapy for well-differentiated squamous cell esophageal cancer, but one must beware of severe adverse events.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.